[CAS NO. 756875-51-1] K6PC-5

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [756875-51-1]

Catalog

HY-124042

Brand

MCE

CAS

756875-51-1

DESCRIPTION [756875-51-1]

Overview

MDL	-
Molecular Weight	343.50
Molecular Formula	C19H37NO4
SMILES	CCCCCCCC(C(C(NC(CO)CO)=O)CCCCCC)=O

For research use only. We do not sell to patients.

Summary

K6PC-5, a ceramide derivative, is a sphingosine kinase 1(SPHK1) activator and elicites a rapid transient increase in intracellular calcium levels. K6PC-5 has the potential for skin diseases involving abnormal keratinocyte, and neurodegeneration and virus infection research ^[1] ^[2] ^[3] .

IC50 & Target

SphK1

In Vitro

K6PC-5 (1-10 μM; 24 h) increases the involucrin and loricrin levels in a dose-dependent manner in normal human epidermal keratinocytes (NHEKs). K6PC-5 promotes differentiation and proliferation of keratinocytes via intracellular Ca ²⁺ signaling. In addition, K6PC-5 stimulates the phosphorylation of p42/44 extracellular signal-regulated kinase and c-Jun N-terminal kinase ^[1] .
K6PC-5 (1-10 μM; 24 h) promotes fibroblasts proliferation and collagen synthesis in human fibroblasts. K6PC-5 induces intracellular Ca ²⁺ concentration ([Ca ²⁺ ] _i ) oscillations in human fibroblasts ^[2] .
K6PC-5 (10, 25, and 50 μM; 48 h) significantly attenuates EBOV-induced infection in EBOV-infected EA.hy926 cells. K6PC-5 significantly reduces the virus titers in supernatants of infected cells and strikingly decreased the amount of VP40 in a concentration-dependent manner ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis ^[1]

Cell Line:	Normal human epidermal keratinocytes (NHEKs)
Concentration:	1 μM, 5 μM, 10 μM
Incubation Time:	24 h
Result:	Increased the involucrin and loricrin levels in a dose-dependent manner.

Cell Proliferation Assay ^[2]

Cell Line:	Human fibroblasts
Concentration:	1 μM, 5 μM, 10 μM
Incubation Time:	24 h
Result:	Promoted fibroblast proliferation and procollagen production in human fibroblasts significantly.

In Vivo

In intrinsically aged hairless mice (56 weeks old), 1% K6PC-5 is applied topically for 2 weeks. This K6PC-5 treatment significantly increases both the number of dermal fibroblasts and collagen production. As a consequence, dermal thickness also increased significantly ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Intrinsically aged hairless mice (56 weeks old) ^[2]
Dosage:	1% (vehicle (PEG:EtOH = 7:3))
Administration:	Topical application; twice daily for 2 weeks
Result:	Enhanced fibroblast proliferation, collagen production, and eventually increased dermal thickness.

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 291.12 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.9112 mL	14.5560 mL	29.1121 mL
5 mM	0.5822 mL	2.9112 mL	5.8224 mL
10 mM	0.2911 mL	1.4556 mL	2.9112 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (7.28 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (7.28 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (7.28 mM); Clear solution

* All of the co-solvents are available by MCE.